

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2014

CORONADO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35366
(Commission File
Number)

20-5157386
(IRS Employer
Identification No.)

24 New England Executive Park, Burlington, MA
(Address of Principal Executive Offices)

01803
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 652-4500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2014, Coronado Biosciences, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release dated August 11, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: August 11, 2014

/s/ Lucy Lu

Name: Lucy Lu

Title: Executive Vice President and Chief Financial Officer



CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS

Burlington, MA – August 11, 2014 – Coronado Biosciences, Inc. (NASDAQ: CNDO) announced today its financial results for the second quarter ended June 30, 2014. Coronado’s net cash and restricted cash totaled \$75.8 million and \$14.0 million respectively at June 30, 2014. The Company posted a quarterly net loss of \$4.7 million and \$12.1 million, or \$0.13 and \$0.34 per share for the three and six months ended June 30, 2014 respectively. These results compare to a net loss of \$10.7 million and \$19.5 million, or \$0.38 and \$0.73 per share for the three and six months ended June 30, 2013 respectively.

“We made progress during the quarter on advancing our initiatives to build a platform of diversified biomedical programs,” said Dr. Lindsay A. Rosenwald, Coronado’s Chairman, President and CEO. “We are committed to maintaining the strength of our balance sheet as we successfully execute on diversifying our pipeline, while we simultaneously evaluate next steps for our existing immunotherapy clinical programs in autism and AML.”

About Coronado Biosciences

Coronado Biosciences is a biopharmaceutical company dedicated to investing in, acquiring, developing and commercializing novel pharmaceutical products. The Company’s portfolio currently includes novel immunotherapy agents for the treatment of autoimmune diseases and cancer. As part of its growth strategy, the company plans to leverage its biopharmaceutical business and drug development expertise to acquire rights to, or to finance, innovative pharmaceutical and biotechnology products, technologies and/or companies, using a variety of approaches including licensing, partnerships, joint ventures, direct financings and/or public and private spin-outs. For more information, visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Lucy Lu, MD, Executive Vice President & Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com

CORONADO BIOSCIENCES, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(\$ in thousands)

	June 30, 2014	December 31, 2013
ASSETS	<i>(Unaudited)</i>	
Cash and cash equivalents	\$ 75,798	\$ 99,521
Short-term investment, at fair value	295	—
Prepaid and other current assets	386	510
Total current assets	76,479	100,031
Property & equipment net	63	447
Restricted cash	14,009	—
Long-term investment, at fair value	250	—
Other	69	104
Total Assets	<u>\$ 90,870</u>	<u>\$ 100,582</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities	\$ 3,437	\$ 11,210
Note payable, non-current	14,009	7,017
Other long-term liabilities	1,056	1,077
Total Liabilities	18,502	19,304
Stockholders' Equity	72,368	81,278
Total Liabilities and Stockholders' Equity	<u>\$ 90,870</u>	<u>\$ 100,582</u>

CORONADO BIOSCIENCES, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(\$ in thousands except for share amounts)
(Unaudited)

	For the three months ended		For the six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
Operating expenses:				
Research and development	\$ 2,377	\$ 7,795	\$ 6,865	\$ 13,769
General and administrative	2,386	2,499	4,481	4,983
Loss from operations	(4,763)	(10,294)	(11,346)	(18,752)
Interest income	171	109	350	185
Interest expense	(119)	(485)	(1,085)	(961)
Net loss attributed to Common Stockholders	\$ (4,711)	\$ (10,670)	\$ (12,081)	\$ (19,528)
Basic and diluted net loss per common share	\$ (0.13)	\$ (0.38)	\$ (0.34)	\$ (0.73)
Weighted average common shares outstanding—basic and diluted	36,005,294	28,095,522	35,953,234	26,646,993